New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
13:40 EDTCI, BSX, MDT, AET, HUM, HS, CNC, AGP, WLP, CVH, UNH, MOH, HNT, WCG, STJBattles over ObamaCare still loom, The Hill says
Medical device companies are trying to use the debate over tax reform to get ObamaCare's tax on medical devices repealed, and some Democrats support that initiative, according to The Hill. Meanwhile, some insurers believe the government may slow the implementation of rules limiting the amount that older people can be charged for insurance, the publication added. Reference Link
News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Check below for free stories on CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 16, 2014
10:36 EDTMDTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:32 EDTSTJSt. Jude Medical sees revenue growth rate accelerating in 2H
Subscribe for More Information
08:18 EDTSTJ St. Jude Medical sees total Q3 CRM sales $660M-$690M
Sees total FY14 CRM sales $2.81B-$2.85B. Sees Q3 AF product sales $240M-$260M, FY14 AF product sales $1.3B-$1.6B. Sees Q3 cardiovascular product sales $315M-$335M, FY14 cardiovacular product sales $1.36B-$1.39B. Sees Q3 neuromodulation product sales $100M-$110M, sees FY14 neuromodulation product sales $440M-$460M. Sees $15M-$20M related to CardioMEMS product line. Says assumes R&D tax credit will be extended for 2014. Says expects to add $10M-$15M in sales related to NeuroTherm product line in 2014, sees acquisition neutral to EPS in 2014. Sees FY14 gross profit margin 71.5%-72%. Still sees FY14 SG&A as a percentage of net sales to be 33.5%-34%. Sees FY14 effective tax rate 18%-18.5%. Comments made on the Q2 earnings conference call.
07:59 EDTMDTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical raises FY14 adjusted EPS view to $3.96-$4.01 from $3.95-$4.00
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q3 adjusted EPS 95c-97c, consensus 96c
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees FY14 adjusted EPS $3.96-$4.01, consensus $3.99
Sees FY14 revenue $5.64B-$5.76B, consensus $5.7B.
07:31 EDTSTJSt. Jude Medical reports Q2 adjusted EPS $1.02, consensus $1.00
Reports Q2 revenue $1.45B, consensus $1.44B.
07:18 EDTMDTScoliosis Research Society to hold annual meeting
Subscribe for More Information
July 15, 2014
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
11:41 EDTSTJSt. Jude Medical technical comments ahead of earnings
Subscribe for More Information
08:00 EDTSTJSt. Jude Medical management to meet with Leerink
Meeting to be held in New York on July 22 hosted by Leerink.
July 14, 2014
19:19 EDTBSXBoston Scientific receives CE Mark for 25 mm Lotus Valve System
Subscribe for More Information
16:15 EDTHUMHumana, Tenet sign new multi-year national agreement
Subscribe for More Information
09:28 EDTCNCCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Subscribe for More Information
09:23 EDTWLPWellPoint Q2 EPS likely to beat consensus by 55c, says Sterne Agee
Subscribe for More Information
09:05 EDTSTJSt. Jude Medical to acquire NeuroTerm for approximately $200M in cash
St. Jude Medical has signed a definitive agreement to acquire privately held NeuroTherm, a manufacturer of interventional pain management therapies, for approximately $200M in cash. NeuroTherm is involved in the treatment of spinal pain using radiofrequency ablation, a segment of the chronic pain market in which St. Jude Medical does not currently participate. The company expects to complete this transaction by the end of the third quarter, subject to customary closing conditions. NeuroTherm is expected to add approximately $10M-$15M to St. Jude Medicalís 2014 sales. Excluding acquisition-related expenses, this transaction will be neutral to St. Jude Medicalís consolidated EPS in 2014 and accretive thereafter on a GAAP basis.
09:02 EDTBSXBoston Scientific receives CE mark for Ranger drug-coated balloon
Boston Scientific has received CE Mark for the Ranger Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.
07:22 EDTWLP, MOH, HUMHealthcare Education Associates to hold a conference
4th Annual RISE California Summit to be held in San Diego on July 13-15.
07:12 EDTMDTCovidien downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use